Nrupen Bhavsar, PhD

Assistant Professor in Medicine
Assistant Professor in Biostatistics and Bioinformatics
Associate of the Duke Initiative for Science & Society
Campus mail Ste 500 NC Mutual Mldg, Box 104427, Durham, NC 27710
Phone (919) 668-7211
Email address nrupen.bhavsar@duke.edu

I am a quantitative epidemiologist with methodological expertise in the design and analysis of observational studies that leverage data from cohort studies, registries, and the electronic health record (EHR). My background, training, and research is in the measurement and characterization of biomarkers, risk factors and treatment outcomes for chronic disease using real-world datasets. My primary research interests are in the use of novel sources of data, including the EHR, to conduct chronic disease research at the intersection of informatics, biostatistics, and epidemiology. My ongoing work aims to integrate informatics, epidemiology, and biostatistics to reduce the burden of chronic disease. I have topical expertise in multiple chronic diseases, including oncology, cardiovascular disease, and chronic kidney disease. In parallel, I have a portfolio of research that aims to understand the impact of social determinants of health, including dynamic neighborhood changes, such as gentrification, on the health of adults and children. 

Education and Training

  • Fellowship, Johns Hopkins University School of Medicine, 2011 - 2013
  • Fellowship, New York University School of Medicine, 2010 - 2011
  • Ph.D., Johns Hopkins University, 2010

Publications

Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Amy P. Abernethy, Ronit Simantov, Azah Borham, and Daniel J. George. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.” Cancer Invest 35, no. 5 (May 28, 2017): 333–44. https://doi.org/10.1080/07357907.2017.1289215.

PMID
28368708
Full Text

Bhavsar, Nrupen A., Benjamin A. Goldstein, Matthew Phelan, and Leigh E. Boulware. “E-Epidemiology to study the Associations of Socioeconomic Status with Risk of Cardiovascular Disease Hospitalization Among Patients with Chronic Kidney Disease.” In Circulation, Vol. 135. LIPPINCOTT WILLIAMS & WILKINS, 2017.

Scholars@Duke

Goldstein, Benjamin A., Nrupen A. Bhavsar, Matthew Phelan, and Michael J. Pencina. “Controlling for Informed Presence Bias Due to the Number of Health Encounters in an Electronic Health Record.” Am J Epidemiol 184, no. 11 (December 1, 2016): 847–55. https://doi.org/10.1093/aje/kww112.

PMID
27852603
Full Text

Qin, Rosie, Adam Olson, Bhavana Singh, Samantha Thomas, Steven Wolf, Nrupen A. Bhavsar, Brent A. Hanks, Joseph K. Salama, and April K. S. Salama. “Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab.” Int J Radiat Oncol Biol Phys 96, no. 1 (September 1, 2016): 72–77. https://doi.org/10.1016/j.ijrobp.2016.04.017.

PMID
27375168
Full Text

Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Ulka N. Vaishampayan, Christos Kyriakopoulos, Walter Michael Stadler, et al. “Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry.” In Journal of Clinical Oncology, 34:e16097–e16097. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e16097.

Full Text

Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Ulka N. Vaishampayan, Christos Kyriakopoulos, Walter Michael Stadler, et al. “Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry.” In Journal of Clinical Oncology, 34:e16084–e16084. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e16084.

Full Text

Howie, L. J., P. K. Marcom, D. L. Topping, J. Force, R. Emerson, N. A. Bhavsar, S. E. Abbott, M. Parks, H. S. Robins, and K. L. Blackwell. “Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab.” In Poster Session Abstracts. American Association for Cancer Research, 2016. https://doi.org/10.1158/1538-7445.sabcs15-p4-14-16.

Full Text

Kyriakopoulos, Christos, Michael Roger Harrison, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Walter Michael Stadler, Hans J. Hammers, et al. “Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.” In Journal of Clinical Oncology, 34:563–563. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.563.

Full Text

Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Walter Michael Stadler, Hans J. Hammers, Ulka N. Vaishampayan, et al. “Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.” In Journal of Clinical Oncology, 34:617–617. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.617.

Full Text

Costello, Brian A., Michael R. Harrison, Nrupen A. Bhavsar, Steven P. Wolf, Christos E. Kyriakopoulos, Walter M. Stadler, Hans Joerg Hammers, et al. “Physician treatment selection in the prospective metastatic renal cell cancer (MaRCC) registry.” In Bju International, 116:7–7. WILEY-BLACKWELL, 2015.

Scholars@Duke

Pages